These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

549 related items for PubMed ID: 11355958

  • 1. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.
    Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, Sausville EA.
    Br J Cancer; 2001 May 18; 84(10):1424-31. PubMed ID: 11355958
    [Abstract] [Full Text] [Related]

  • 2. The hollow fibre model in cancer drug screening: the NCI experience.
    Decker S, Hollingshead M, Bonomi CA, Carter JP, Sausville EA.
    Eur J Cancer; 2004 Apr 18; 40(6):821-6. PubMed ID: 15120037
    [Abstract] [Full Text] [Related]

  • 3. The hollow fiber assay: continued characterization with novel approaches.
    Hall LA, Krauthauser CM, Wexler RS, Hollingshead MG, Slee AM, Kerr JS.
    Anticancer Res; 2000 Apr 18; 20(2A):903-11. PubMed ID: 10810375
    [Abstract] [Full Text] [Related]

  • 4. Chemoinformatic analysis of NCI preclinical tumor data: evaluating compound efficacy from mouse xenograft data, NCI-60 screening data, and compound descriptors.
    Wallqvist A, Huang R, Covell DG.
    J Chem Inf Model; 2007 Apr 18; 47(4):1414-27. PubMed ID: 17555311
    [Abstract] [Full Text] [Related]

  • 5. Flasks, fibres and flanks--pre-clinical tumour models for predicting clinical antitumour activity.
    Newell DR.
    Br J Cancer; 2001 May 18; 84(10):1289-90. PubMed ID: 11355935
    [No Abstract] [Full Text] [Related]

  • 6. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.
    Kelland LR.
    Eur J Cancer; 2004 Apr 18; 40(6):827-36. PubMed ID: 15120038
    [Abstract] [Full Text] [Related]

  • 7. Antitumor activity of triazine mimic antibiotics for DNA-binding implications (impressive activity in vitro against a variety of tumor types in the NCI-60 screen): NSC 710607 to fight HCT-116 human colon carcinoma cell lines in vivo using the hollow fiber assay and xenograft mouse models.
    Spychala J.
    J Cancer Res Clin Oncol; 2023 Aug 18; 149(9):6501-6511. PubMed ID: 36780052
    [Abstract] [Full Text] [Related]

  • 8. Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action.
    Huang R, Wallqvist A, Covell DG.
    J Med Chem; 2006 Mar 23; 49(6):1964-79. PubMed ID: 16539384
    [Abstract] [Full Text] [Related]

  • 9. The hollow fibre model--facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare.
    Suggitt M, Cooper PA, Shnyder SD, Bibby MC.
    Int J Oncol; 2006 Dec 23; 29(6):1493-9. PubMed ID: 17088988
    [Abstract] [Full Text] [Related]

  • 10. Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature.
    Shnyder SD, Hasan J, Cooper PA, Pilarinou E, Jubb E, Jayson GC, Bibby MC.
    Anticancer Res; 2005 Dec 23; 25(3B):1889-94. PubMed ID: 16158922
    [Abstract] [Full Text] [Related]

  • 11. Characterization of the hollow fiber assay for the determination of microtubule disruption in vivo.
    Suggitt M, Swaine DJ, Pettit GR, Bibby MC.
    Clin Cancer Res; 2004 Oct 01; 10(19):6677-85. PubMed ID: 15475458
    [Abstract] [Full Text] [Related]

  • 12. Methyl protogracillin (NSC-698792): the spectrum of cytotoxicity against 60 human cancer cell lines in the National Cancer Institute's anticancer drug screen panel.
    Hu K, Yao X.
    Anticancer Drugs; 2001 Jul 01; 12(6):541-7. PubMed ID: 11460001
    [Abstract] [Full Text] [Related]

  • 13. Development of breast cancer chemopreventive drugs.
    Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet R, Doody LA, Greenwald P.
    J Cell Biochem Suppl; 1993 Jul 01; 17G():2-13. PubMed ID: 8007699
    [Abstract] [Full Text] [Related]

  • 14. Use of the in vivo hollow fiber assay in natural products anticancer drug discovery.
    Mi Q, Pezzuto JM, Farnsworth NR, Wani MC, Kinghorn AD, Swanson SM.
    J Nat Prod; 2009 Mar 27; 72(3):573-80. PubMed ID: 19161316
    [Abstract] [Full Text] [Related]

  • 15. Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats.
    Jonsson E, Friberg LE, Karlsson MO, Hassan SB, Freijs A, Hansen K, Larsson R.
    Cancer Chemother Pharmacol; 2000 Mar 27; 46(6):493-500. PubMed ID: 11138463
    [Abstract] [Full Text] [Related]

  • 16. Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs for the treatment of human brain tumor xenografts.
    Arguello F, Alexander MA, Greene JF, Stinson SF, Jorden JL, Smith EM, Kalavar NT, Alvord WG, Klabansky RL, Sausville EA.
    J Cancer Res Clin Oncol; 1998 Jan 27; 124(1):19-26. PubMed ID: 9498830
    [Abstract] [Full Text] [Related]

  • 17. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations.
    Fojo T, Farrell N, Ortuzar W, Tanimura H, Weinstein J, Myers TG.
    Crit Rev Oncol Hematol; 2005 Jan 27; 53(1):25-34. PubMed ID: 15607933
    [Abstract] [Full Text] [Related]

  • 18. Update on NCI in vitro drug screen utilities.
    Holbeck SL.
    Eur J Cancer; 2004 Apr 27; 40(6):785-93. PubMed ID: 15120034
    [Abstract] [Full Text] [Related]

  • 19. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models.
    Voskoglou-Nomikos T, Pater JL, Seymour L.
    Clin Cancer Res; 2003 Sep 15; 9(11):4227-39. PubMed ID: 14519650
    [Abstract] [Full Text] [Related]

  • 20. Developmental therapeutics program at the NCI: molecular target and drug discovery process.
    Monga M, Sausville EA.
    Leukemia; 2002 Apr 15; 16(4):520-6. PubMed ID: 11960328
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.